Investor concerns grow over Cohen & Steers' high P/E ratio in relation to dwindling earnings and low predicted growth rate. Speculations suggest the excessive P/E ratio is driven by investor confidence in a business turnaround which may not be sustainable given current earnings and growth rates.
An insider selling shares at a price lower than market value could reflect their belief in a fair lower price. Absence of purchases in the past year despite high insider ownership might cause concern. Usually, however, a high level of insider ownership is seen positively as it implies management's alignment with shareholder interests.
Gapping up In reaction to earnings/guidance: •$New Relic(NEWR.US)$+3.8% (guidance),$美国航空(AAL.US)$+2% (guidance) Other news: •$DICE THERAPEUTICS, INC.(DICE.US)$+66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17) •$Albireo Pharma(ALBO.US)$+17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
科恩-斯蒂尔斯金融股票讨论区
专栏Today's Pre-Market Stock Movers: AAL, ZS, DICE, Crude and More
In reaction to earnings/guidance:
• $New Relic(NEWR.US)$ +3.8% (guidance),$美国航空(AAL.US)$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US)$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US)$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
暂无评论